ReviewHuman genetics2011
Somatic variation and cancer: therapies lost in the mix.
Review in Human genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Molecular Subtypes of Pancreatic Cancer: A Review of the Literature.Current issues in molecular biology · 2026Review
- GATA6 in pancreatic cancer initiation and progression.Genes & diseases · 2025Review
- Comparison between three types of needles for endoscopic ultrasound-guided tissue acquisition of pancreatic solid masses: a multicenter observational study.Scientific reports · 2023Observational
- Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer.Oncology and therapy · 2023Article
- Article
- Editorial: Genetics and Molecular Mechanisms of Oral and Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Article
- Molecular subtypes of pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2019Review
- Review
- Review
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer.Genome medicine · 2013Article
- Article
- Article
- The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.Nature reviews. Gastroenterology & hepatology · 2011Review
- Cyclin D as a therapeutic target in cancer.Nature reviews. Cancer · 2011Review
- Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.Cancer genomics & proteomicsReview
- The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer arises as a consequence of mutations in genomes of cancer cells, which over time allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer genomes is revealing an increasing number of potential driver mutations that may allow specific targeting of cancer genes, proteins, and pathways. Comprehensive views of cancer genomes are also revealing enormous heterogeneity of mutation profiles, even among tumours derived from the same organs and having similar pathological characteristics. There are now many examples where mutation profiles observed in tumours have been shown to correlate with clinical features of disease, drug response, and patient outcomes. When ignored, molecular heterogeneity can lead to failures in drug development, as drugs that may have efficacy in subgroups of patients with specific molecular phenotypes may show marginal response when tested in large groups of unselected patients. This article explores issues relevant to the clinical translation of sequence-based mutation profiles in the clinical development of targeted therapies and in the future management of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.